WCM Investment Management LLC Takes $1.05 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

WCM Investment Management LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 60,170 shares of the company's stock, valued at approximately $1,051,000.

Other large investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $60,000. State of New Jersey Common Pension Fund D increased its position in shares of Teva Pharmaceutical Industries by 3.7% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 473,509 shares of the company's stock valued at $8,533,000 after purchasing an additional 16,700 shares during the last quarter. Atria Investments Inc boosted its holdings in Teva Pharmaceutical Industries by 135.4% during the 3rd quarter. Atria Investments Inc now owns 30,856 shares of the company's stock valued at $556,000 after acquiring an additional 17,746 shares during the period. Greenwood Capital Associates LLC purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at $4,267,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at $2,019,000. Institutional investors own 54.05% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. Barclays boosted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Finally, UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded down $0.06 during trading hours on Wednesday, hitting $17.05. The company had a trading volume of 2,037,328 shares, compared to its average volume of 9,243,054. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a one year low of $8.64 and a one year high of $19.31. The company's fifty day moving average price is $17.91 and its two-hundred day moving average price is $17.18.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.